These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 21879468)
21. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403 [TBL] [Abstract][Full Text] [Related]
22. Biological variation in bone-derived biochemical markers in serum. Panteghini M; Pagani F Scand J Clin Lab Invest; 1995 Nov; 55(7):609-16. PubMed ID: 8633185 [TBL] [Abstract][Full Text] [Related]
23. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290 [TBL] [Abstract][Full Text] [Related]
24. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213 [TBL] [Abstract][Full Text] [Related]
25. Expression of Interleukin-6 (IL-6) and IL-6 receptor mRNA in human bone samples from pre- and postmenopausal women. Seck T; Diel I; Bismar H; Ziegler R; Pfeilschifter J Bone; 2002 Jan; 30(1):217-22. PubMed ID: 11792588 [TBL] [Abstract][Full Text] [Related]
26. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. Lakatos P; Foldes J; Horvath C; Kiss L; Tatrai A; Takacs I; Tarjan G; Stern PH J Clin Endocrinol Metab; 1997 Jan; 82(1):78-81. PubMed ID: 8989237 [TBL] [Abstract][Full Text] [Related]
27. Circulating cytokine levels in osteoporotic and normal women. Khosla S; Peterson JM; Egan K; Jones JD; Riggs BL J Clin Endocrinol Metab; 1994 Sep; 79(3):707-11. PubMed ID: 8077350 [TBL] [Abstract][Full Text] [Related]
28. Serum CX3CL1/fractalkine concentrations are positively associated with disease severity in postmenopausal osteoporotic patients. Chen YD; Huang CY; Liu HY; Yao WF; Wu WG; Lu YL; Wang W Br J Biomed Sci; 2016 Jul; 73(3):121-128. PubMed ID: 27476376 [TBL] [Abstract][Full Text] [Related]
29. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis. Verit FF; Geyikli I; Yazgan P; Celik A Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321 [TBL] [Abstract][Full Text] [Related]
30. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Shaarawy M; Zaki S; Sheiba M; El-Minawi AM Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333 [TBL] [Abstract][Full Text] [Related]
31. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620 [TBL] [Abstract][Full Text] [Related]
32. [Age-related changes serum levels of MMP-1 and MMP-2 in women: their relationship with bone biochemical markers and bone mineral density]. Zhang H; Luo XH; Xie H; Wu XP; Shan PF; Cao XZ; Liao EY Zhonghua Nei Ke Za Zhi; 2006 Apr; 45(4):306-9. PubMed ID: 16780680 [TBL] [Abstract][Full Text] [Related]
33. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944 [TBL] [Abstract][Full Text] [Related]
34. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170 [TBL] [Abstract][Full Text] [Related]
35. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688 [TBL] [Abstract][Full Text] [Related]
36. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. Pater A; Sypniewska G; Pilecki O J Pediatr Endocrinol Metab; 2010; 23(1-2):81-6. PubMed ID: 20432810 [TBL] [Abstract][Full Text] [Related]
37. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. Hannon R; Blumsohn A; Naylor K; Eastell R J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076 [TBL] [Abstract][Full Text] [Related]
38. Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass. Park SM; Joung JY; Cho YY; Sohn SY; Hur KY; Kim JH; Kim SW; Chung JH; Lee MK; Min YK Eur J Clin Nutr; 2015 Mar; 69(3):361-6. PubMed ID: 25649239 [TBL] [Abstract][Full Text] [Related]
39. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. Jiang LS; Zhang ZM; Jiang SD; Chen WH; Dai LY J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758 [TBL] [Abstract][Full Text] [Related]
40. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. Weaver CM; Peacock M; Martin BR; McCabe GP; Zhao J; Smith DL; Wastney ME J Bone Miner Res; 1997 Oct; 12(10):1714-20. PubMed ID: 9333133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]